BI-836880

DB17484InvestigationalProtein Based Therapies

BI-836880 is a humanized bispecific nanobody that targets VEGF and Ang2.

Mechanism: Pharmacologically active on Vascular endothelial growth factor A, long form and Angiopoietin-2
Curator reviewed
Code names: BI-836880

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with BI-836880, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.